抗生素开发商Smartbax完成470万欧元Pre-A轮融资，用于进一步开发一种新型抗生素，直至临床前阶段-动脉网

smartbax secures 4.7 million euros in Pre-Series A funding for the further development of a novel antibiotic up to preclinical stage

D-Pharm 等信源发布 2025-10-24 11:37



可切换为仅中文







smartbax, a biotech company developing next-generation antibiotics, announced the successful first closing of its €4.7 million Pre-

智能背包，一家开发下一代抗生素的生物技术公司，宣布成功完成了其470万欧元的预融资。

Series A financing

A轮融资

round. The round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors HTGF - High-Tech Gründerfonds and Boehringer Ingelheim Venture Fund (BIVF). A second tranche for this financing round remains open to new investors..

这一轮融资由新投资者Anobis Asset和Bayern Kapital领投，UnternehmerTUM Funding for Innovators以及现有投资者HTGF（高科技创业基金）和Boehringer Ingelheim Venture Fund（BIVF）也参与其中。此轮融资的第二部分仍对新投资者开放。

smartbax will use the fresh capital to further develop its proprietary pipeline of small molecule antibiotics designed to overcome bacterial resistance with innovative approaches and novel mechanisms of action. The most advanced candidate is an inhibitor that blocks a previously unused step in the synthesis of lipopolysaccharides (LPS), important structural components of the outer membrane of Gram-negative bacteria.

Smartbax将利用这笔新资金进一步开发其专有的小分子抗生素管线，这些抗生素旨在通过创新方法和新颖的作用机制克服细菌耐药性。最先进的候选药物是一种抑制剂，可阻断革兰氏阴性菌外膜重要结构成分脂多糖（LPS）合成过程中一个以前未被利用的步骤。

This new inhibitor has already demonstrated its efficacy in vivo, including against multi-resistant strains. It shows potential for oral application and is now to be taken through to preclinical development..

这种新的抑制剂已经在体内证明了其效力，包括对抗多耐药菌株。它显示出口服应用的潜力，现在将进入临床前开发阶段。

In parallel, smartbax is further developing its platform of small molecule activators of bacterial hydrolases. In contrast to traditional antibiotics, which inhibit bacterial functions, these compounds stimulate hydrolase activity, causing the bacteria to digest themselves from the inside. This innovative mechanism of action has not yet been exploited in commercial antibiotics and offers a promising strategy to overcome established resistance mechanisms.

同时，Smartbax 正在进一步开发其细菌水解酶小分子激活剂的平台。与抑制细菌功能的传统抗生素不同，这些化合物刺激水解酶活性，使细菌从内部自我消化。这种创新的作用机制尚未在商业抗生素中被利用，为克服已有的耐药机制提供了一种有前景的策略。

smartbax has identified two classes of activators that act against different target structures in Gram-positive and Gram-negative bacteria. Both have promising drug properties, can eliminate biofilms and do not cause the development of resistance. With the current funding, the company will further develop these activators to select lead candidates and demonstrate in vivo proof of concept..

smartbax 已经确定了两类激活剂，它们分别作用于革兰氏阳性菌和革兰氏阴性菌的不同靶点结构。这两类激活剂均具有良好的药物特性，能够消除生物膜且不会导致耐药性的发展。在当前资金的支持下，该公司将进一步开发这些激活剂，筛选先导化合物，并在体内验证概念。

'Small molecule antibiotics remain one of the most effective tools in the fight against the rapidly growing threat of antimicrobial resistance. smartbax is currently the only German biotech company exclusively dedicated to the development of this critical class of compounds. We are proud to be advancing complementary approaches, both with a classical inhibitor against a novel target and with enzyme activators that exploit an entirely new mechanism of action in the antibiotic space,' said Dr.

“小分子抗生素仍然是应对日益增长的抗菌素耐药性威胁的最有效工具之一。smartbax 是目前德国唯一一家专注于开发这类关键化合物的生物技术公司。我们很自豪正在推进互补的方法，既通过针对一个新靶点的经典抑制剂，也通过利用抗生素领域全新作用机制的酶激活剂。”博士说道。

Robert Macsics, CEO of smartbax. 'Our programs focus on WHO priority pathogens and aim to create new treatment options for critically ill patients who currently have limited options. We are very pleased to have this strong consortium of investors who share our commitment and will work with us to address this urgent public health threat.'.

smartbax首席执行官罗伯特·马克西克斯表示：“我们的项目专注于世界卫生组织优先关注的病原体，并旨在为目前治疗选择有限的重症患者创造新的治疗方案。我们非常高兴能拥有这个强大的投资者联盟，他们与我们有着共同的承诺，并将与我们一起应对这一紧迫的公共卫生威胁。”

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

注意：本文已通过计算机系统翻译，未经人工干预。LUMITOS 提供这些自动翻译，以呈现更广泛的当前新闻。由于本文是通过自动翻译翻译的，因此可能存在词汇、句法或语法方面的错误。

The original article in German can be found .

德语原文可以在以下位置找到。

here

这里

。

https://www.bionity.com/en/news/1187407/smartbax-secures-4-7-million-euros-in-pre-series-a-funding-for-the-further-development-of-a-novel-antibiotic-up-to-preclinical-stage.html

https://www.bionity.com/zh/news/1187407/smartbax-获得470万欧元的pre-series-a轮融资以进一步开发新型抗生素至临床前阶段.html

Know your enemy

了解你的敌人

An arsenal to fight antibiotic-resistant bacteria

对抗抗生素耐药菌的武器库

Read news

读新闻